GTHP · Guided Therapeutics Inc · Executive Compensation
$0.19
+0.03 (+18.75%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The factors below raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.”View the 10-Q filed Aug 13, 2026
Market Cap
$18.34M
Shares
96.54M
Volume · Oct 20
154.21K
Avg daily vol (3M)
36.07K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Alan Grujic | member of the Board | Appointed | 2023-03-09 |
| Mark Faupel | President and Chief Executive Officer | Appointed | 2023-03-09 |
| Gene Cartwright | member of the Board | Retired | 2023-03-09 |
| Gene Cartwright | President and Chief Executive Officer | Retired | 2023-03-09 |
Leadership
- Mark Faupel CEO
- Mark L. Faupel COO, Board Member
- Alan Grujic Board Member
- John E. Imhoff Board Member
- Richard P. Blumberg Board Member